

Monday, 5<sup>th</sup> December 2022

### Medlab Cyber Incident - Update

Further to the announcement made on 27<sup>th</sup> October 2022 Australian Clinical Labs Limited (**ASX: ACL**) (**ACL**) advises that the Office of the Australian Information Commissioner (**OAIC**) has expressed its intention to investigate the acts and practices of Medlab Pathology (**Medlab**) in relation to the data breach previously notified.

ACL has kept the OAIC abreast of the progress of the forensic investigations into the incident and has responded to all requests for information.

Given the current environment, this development is expected, and ACL will continue to co-operate fully with the OAIC.

Medlab has now contacted all individuals whose contact information was available to Medlab, to provide them with information about the incident, how it affects them and steps that can be taken to protect their information. Detailed information about the incident is also available on the Medlab and ACL websites.

In addition, ACL is continuing to support notified individuals:

- by providing a dedicated inbound response team, established to answer questions and provide them with guidance and remediation advice in relation to the incident;
- through its 'care team', established to minimise distress to those whose sensitive information may have been involved in the incident; and
- by offering free-of-charge credit monitoring and / or ID document replacement to individuals whose affected information types may put them at risk of credit and/or identity fraud. ACL is continuing to work alongside Federal and State government authorities in this regard.

To date, there is no evidence of misuse of any of the information involved in the incident. The compromised Medlab server was de-commissioned and is no longer in use. ACL's broader systems and databases remain unaffected by the incident.

**-ENDS -**

This announcement was authorised for release to ASX by the ACL Board.

For further information regarding this announcement, please contact:

#### **Investors**

Eleanor Padman  
Company Secretary  
Email: [investors@clinicallabs.com.au](mailto:investors@clinicallabs.com.au)  
Phone: +61 (0) 422 002 918

#### **Media**

Clive Mathieson, Sue Cato  
Email: [clive@catoandclive.com](mailto:clive@catoandclive.com)  
[cato@catoandclive.com](mailto:cato@catoandclive.com)  
Phone: +61 (0) 411 888 425  
+61 (0) 419 282 319

#### **About Australian Clinical Labs**

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.